{"id":"W4308254443","doi":"10.1007/s41669-022-00375-x","title":"A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"ABB (Canada); Foothills Medical Centre","funders":"AbbVie","keywords":"Obinutuzumab; Venetoclax; Medicine; Chlorambucil; Rituximab; Bendamustine; Internal medicine; Fludarabine; Chronic lymphocytic leukemia; Ibrutinib; Oncology; Population; Ofatumumab; Cyclophosphamide; Leukemia; Chemotherapy; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00122983,0.0002502367,0.001059988,0.0005597911,0.00009043021,0.0000374924,0.0005993592,0.00004473836,0.001150405],"category_scores_gemma":[0.0000831369,0.000269461,0.00009500099,0.001169,0.00009036573,0.0001407239,0.000767033,0.0003641324,0.00000445322],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.7097142,"about_ca_system_score_gemma":0.3051045,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9793026,"about_ca_topic_score_gemma":0.8743691,"domain_scores_codex":[0.9975809,0.0002911591,0.0006828629,0.000645966,0.0002743404,0.0005247724],"domain_scores_gemma":[0.9983527,0.0007158234,0.0001932219,0.0004825981,0.00005156786,0.0002040824],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.004115146,0.00003813261,0.005819956,0.000307809,0.0009008592,0.0003419507,0.000431173,0.9822661,0.000561547,0.0001122432,0.0001069985,0.004998039],"study_design_scores_gemma":[0.04388485,0.0004320919,0.00980232,0.00006857964,0.0002556028,0.00008343171,0.0001582852,0.9405372,0.001572416,0.0001276597,0.002817429,0.0002601136],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939042,0.001118043,0.000001948829,0.00008040199,0.00009127591,0.004116302,0.0001123476,0.000008394027,0.000567104],"genre_scores_gemma":[0.9964226,0.0009889334,0.0000127826,0.0004506516,0.00002784215,0.001839851,0.0001060234,0.00004201836,0.0001092378],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4046097,"threshold_uncertainty_score":0.9999757,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04922340262774139,"score_gpt":0.3689317120683685,"score_spread":0.3197083094406271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}